Description：ELISA for the detection of Alnuctamab in human serum and plasma.
Lead time for this kit is 5 weeks.
About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.An asymmetric immunoglobulin G1 （IgG1）-based, B-cell maturation antigen （BCMA） x CD3 T-cell bispecific monoclonal antibody, Alnuctamab is currently under Phase-1 trial for multiple myeloma.
